pressmaster-shutterstock-com-3

Pressmaster / Shutterstock.com

10 December 2015Big PharmaChristopher Stothers and Paul Abbott

Managing SPCs under the unitary patent system

In this article, we identify the key issues and provide tips to help potential users best prepare for the new system.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

SPCs and the unitary patent system: what now?

6 September 2016 Brexit will have significant consequences for the UK regarding SPCs and the unitary patent system, while the UPC’s proposed start date of early 2017 looks highly unlikely, say Christopher Stothers and Paul Abbott of Arnold & Porter.

Why the UPC will be rewarding for US businesses

4 April 2023 Pinsent Masons and Sterne, Kessler, Goldstein, & Fox consider why the Unified Patent Court, due to open on June 1, 2023, will make Europe a more attractive patent litigation venue for US businesses.

More on this story

Why the UPC will be rewarding for US businesses

4 April 2023 Pinsent Masons and Sterne, Kessler, Goldstein, & Fox consider why the Unified Patent Court, due to open on June 1, 2023, will make Europe a more attractive patent litigation venue for US businesses.

SPCs and the unitary patent system: what now?

6 September 2016 Brexit will have significant consequences for the UK regarding SPCs and the unitary patent system, while the UPC’s proposed start date of early 2017 looks highly unlikely, say Christopher Stothers and Paul Abbott of Arnold & Porter.

More on this story

Why the UPC will be rewarding for US businesses

4 April 2023 Pinsent Masons and Sterne, Kessler, Goldstein, & Fox consider why the Unified Patent Court, due to open on June 1, 2023, will make Europe a more attractive patent litigation venue for US businesses.

SPCs and the unitary patent system: what now?

6 September 2016 Brexit will have significant consequences for the UK regarding SPCs and the unitary patent system, while the UPC’s proposed start date of early 2017 looks highly unlikely, say Christopher Stothers and Paul Abbott of Arnold & Porter.

More features

Sandoz lands reduced antitrust award of $70m

Teva faces $500m fine for antitrust breaches over MS drug

Pfizer infringed haemophilia therapy patent, says court

Big Pharma counsel embrace AI but data and legal risks loom

MSN scores win in battle with Novartis over heart drug generic

HR, lobbying and business strategy…all in a day’s work for today’s counsel

LSPN Fall: Gilead GC shares top drafting tips

LSPN Fall: Why Big Pharma is facing 'a balancing act'